IVA News and Press, Inventiva S.A. From 12/12/22

Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis, announced the receipt of the €25M payment under the first tranche of the unsecured loan agreement executed with the Eur...

Inventiva ( NASDAQ: IVA ) ( OTCPK:IVEVF ) said AbbVie ( NYSE: ABBV ) has decided to stop the development of cedirogant (ABBV-157) to treat autoimmune diseases after analysis of a nonclinical toxicology study. In 2012, the two companies entered a collab...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! There’s major marijuana news moving stocks thi...

Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...

Inventiva S.A. (IVA) Q2 2022 Earnings Conference Call September 22, 2022, 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial ...

Inventiva press release ( NASDAQ: IVA ): 1H GAAP EPS of -$0.72. Revenue of $67K (-51.8% Y/Y). For further details see: Inventiva GAAP EPS of -$0.72, revenue of $67M

France-based clinical-stage biopharma Inventiva ( NASDAQ: IVA ) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. ...

Inventiva press release (NASDAQ:IVA): Cash position at €80.5m as of March 31, 2022 The Group did not generate any revenue in Q1 2022 Signature of a €50 million bullet credit facility agreement with the European Investment Bank For further details see: Inventiva r...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Inventiva S.A. (IVA) Q4 2021 Earnings Conference Call March 08, 2022 08:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier -...